Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 151 to 165 of 660 results for position

  1. Deep brain stimulation for intractable trigeminal autonomic cephalalgias (IPG381)

    Evidence-based recommendations on deep brain stimulation for intractable trigeminal autonomic cephalalgias. This involves delivering electrical impulses to a precise area of the brain using an electrode to mask the pain.

  2. End of Life Care Rapid Transport Service

    therefore unable to use clinical judgement, being put in the difficult position of needing to consider CPR for a patient that has died...

  3. Laparoscopic partial nephrectomy (IPG151)

    Evidence-based recommendations on laparoscopic partial nephrectomy. This involves making small ‘keyhole’ openings, either in the back or in the abdomen, to remove the section of kidney that contains the tumour.

  4. Jaundice in newborn babies under 28 days (CG98)

    This guideline covers diagnosing and treating jaundice, which is caused by increased levels of bilirubin in the blood, in newborn babies (neonates). It aims to help detect or prevent very high levels of bilirubin, which can be harmful if not treated.

  5. SimpliCT laser-guided needle placement in interventional radiology (MIB98)

    NICE has developed a medtech innovation briefing (MIB) on SimpliCT laser-guided needle placement in interventional radiology .

  6. Suture fixation of acute disruption of the distal tibiofibular syndesmosis (IPG521)

    Evidence-based recommendations on suture fixation of acute disruption of the distal tibiofibular syndesmosis. This involves threading a suture through a tunnel made in the bones (tibia and fibula) and tying the ends together to fix the joint.

  7. Transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults (IPG634)

    Evidence-based recommendations on transcutaneous neuromuscular electrical stimulation for oropharyngeal dysphagia in adults. This involves electrically stimulating nerves in the throat or neck, while the person swallows. The aim is to strengthen the muscles involved in swallowing.

  8. Photodynamic therapy for bile duct cancer (IPG134)

    Evidence-based recommendations on photodynamic therapy for bile duct cancer. This involves injecting a photosensitising agent into the body that is then activated by a small laser to destroy cancer cells and shrink the blockage.

  9. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

  10. Nivolumab for treating advanced (unresectable or metastatic) melanoma (TA384)

    Evidence-based recommendations on nivolumab (Opdivo) for treating advanced (unresectable or metastatic) melanoma in adults.

  11. Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab (TA357)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma after disease progression with ipilimumab in adults.

  12. Bortezomib for previously untreated mantle cell lymphoma (TA370)

    Evidence-based recommendations on bortezomib (Velcade) for untreated mantle cell lymphoma in adults.

  13. Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism (TA341)

    Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.

  14. Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism (TA354)

    Evidence-based recommendations on edoxaban (Lixiana) for treating deep vein thrombosis and pulmonary embolism in adults and preventing them happening again.

  15. Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

    Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for adults with unresectable or metastatic melanoma that has a BRAF V600 mutation.